H.C. Wainwright Asserts Buy Stance on Gossamer Bio Inc. (GOSS) on Pulmonary Arterial Hypertension Drug Prospects

Group 1 - Gossamer Bio Inc. (NASDAQ:GOSS) has shown strong momentum, rallying by more than 100% year to date, and has received a 'Buy' rating from H.C. Wainwright with a $10 price target [1][2] - The positive outlook from H.C. Wainwright is based on anticipated key clinical data for the investigational drug seralutinib, aimed at treating pulmonary arterial hypertension, expected early next year [2][3] - Data from the Phase 2 TORREY trial indicated sustained hemodynamic and functional improvements through 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance among patients [3] Group 2 - Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [4]